Biomarker Panel Screening for Skin Moisturizing Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying new skin moisturizing actives are time-consuming, expensive, and ineffective for in vitro screening, particularly for targeting specific patient populations with dry skin exacerbated by seasonal changes or treatments, and lack sensitivity to distinguish between inherently dry and normal skin.
Innovation Solution
Development of novel biomarker panels using genomics and bioinformatics analysis to identify cosmetic test agents effective as skin moisturizers, specifically targeting dry skin through transcriptional profiling of genes like REL, ITGB1, TGFBR2, YY1AP1, MAP3K, CASP3, TERT, MDM2, and LAMC2, allowing for efficient in vitro screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional clinical studies are used to identify skin moisturizing actives, then efficacy can be demonstrated, but the process becomes prohibitively time-consuming and expensive
Solution Approach 1:
The patent creates in vitro models that replicate human skin structure and function, allowing screening of moisturizing actives in cell cultures rather than requiring extensive clinical studies on human subjects. This copying approach maintains efficacy assessment capability while dramatically reducing time and cost.
Solution Approach 2:
The patent performs preliminary screening of potential moisturizing actives using in vitro assays before advancing candidates to clinical studies. This preliminary action filters out ineffective compounds early, reducing the number of substances that require time-consuming and expensive clinical evaluation.
2Productivity
If conventional in vitro studies test hundreds or thousands of potential agents, then comprehensive screening is achieved, but the complex and weakly detectable responses hinder identification of effective agents
Solution Approach 1:
The patent focuses on measuring specific local responses in skin cells rather than attempting to detect weak global responses across entire organisms. By targeting specific cellular endpoints and biomarkers in in vitro models, the detection sensitivity is significantly improved while maintaining comprehensive screening capability.
Solution Approach 2:
The patent transforms the measurement parameters from weak physiological responses to stronger, more detectable cellular and molecular endpoints. By measuring gene expression, protein levels, or cellular viability changes in response to cosmetic agents, the detection sensitivity is enhanced while maintaining screening productivity.
3Adaptability or versatility
If traditional biomarkers are used to assess skin dryness, then general moisturization effects can be measured, but the ability to distinguish between inherently dry skin and normal moisturized skin is lost
Solution Approach 1:
The patent segments the skin population into distinct categories (inherently dry skin vs. normal moisturized skin) and develops specific biomarker panels for each segment. This segmentation allows precise differentiation between skin types while maintaining general applicability through the use of multiple targeted assays.
Solution Approach 2:
The patent introduces specific biomarkers and molecular indicators as intermediaries that mediate between the complex phenotype of skin dryness and measurable parameters. These intermediary biomarkers provide precise differentiation between skin types while maintaining broad applicability across different study conditions.
4Adaptability or versatility
If clinical studies are conducted during winter months to address dry skin, then seasonal dry skin can be studied, but the limited testing window increases time loss and reduces productivity
Solution Approach 1:
The patent replaces the mechanical constraint of seasonal field studies with in vitro laboratory-based models that can be conducted year-round. By substituting human subject studies during specific seasons with controlled cell culture experiments, the system eliminates seasonal limitations while maintaining relevance to seasonal dry skin through appropriate model selection and biomarker measurement.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Methods of identifying potential skin moisturizing actives for the treatment of dry skin and method of formulating a moisturizing skin care composition using actives identified by the method. Moisturizing agents can be identified by comparing the transcriptional profile of a skin tissue sample contacted by a test agent to a negative or positive control to determine if the regulation of certain genes corresponds to the appropriate direction of regulation indicated by the control. Agents identified as skin moisturizing agents can then be incorporated into a skin moisturizing composition.